These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 19657672)

  • 1. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
    Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome.
    Xu J; Shetty PB; Feng W; Chenault C; Bast RC; Issa JP; Hilsenbeck SG; Yu Y
    BMC Cancer; 2012 Jun; 12():243. PubMed ID: 22695491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypermethylation of RARβ2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma.
    Miladi-Abdennadher I; Abdelmaksoud-Damak R; Ayadi L; Khabir A; Frikha F; Kallel L; Amouri A; Frikha M; Sellami-Boudawara T; Gargouri A; Mokdad-Gargouri R
    Tumour Biol; 2010 Oct; 31(5):503-11. PubMed ID: 20571967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.
    Sunami E; Shinozaki M; Sim MS; Nguyen SL; Vu AT; Giuliano AE; Hoon DS
    Breast Cancer Res; 2008; 10(3):R46. PubMed ID: 18485221
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
    Ramezani F; Salami S; Omrani MD; Maleki D
    Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
    Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
    Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
    Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
    BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Promoter hypermethylation of p16, BRCA1 and RASSF1A genes in triple-negative breast cancer patients from Serbia.
    Kozomara Z; Supic G; Krivokuca A; Magic Z; Dzodic R; Milovanovic Z; Brankovic-Magic M
    J BUON; 2018; 23(3):684-691. PubMed ID: 30003738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients.
    Sharma G; Mirza S; Yang YH; Parshad R; Hazrah P; Datta Gupta S; Ralhan R
    Cell Oncol; 2009; 31(6):487-500. PubMed ID: 19940364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivation of RASSF1A, RARbeta2 and DAP-kinase by promoter methylation correlates with lymph node metastasis in nasopharyngeal carcinoma.
    Fendri A; Masmoudi A; Khabir A; Sellami-Boudawara T; Daoud J; Frikha M; Ghorbel A; Gargouri A; Mokdad-Gargouri R
    Cancer Biol Ther; 2009 Mar; 8(5):444-51. PubMed ID: 19221469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of expression and aberrant methylation of the CDH1 (E-cadherin) gene in breast cancer patients from Kashmir.
    Asiaf A; Ahmad ST; Aziz SA; Malik AA; Rasool Z; Masood A; Zargar MA
    Asian Pac J Cancer Prev; 2014; 15(15):6397-403. PubMed ID: 25124632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
    Huang R; Ding P; Yang F
    Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation.
    Krassenstein R; Sauter E; Dulaimi E; Battagli C; Ehya H; Klein-Szanto A; Cairns P
    Clin Cancer Res; 2004 Jan; 10(1 Pt 1):28-32. PubMed ID: 14734448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors.
    Klajic J; Fleischer T; Dejeux E; Edvardsen H; Warnberg F; Bukholm I; Lønning PE; Solvang H; Børresen-Dale AL; Tost J; Kristensen VN
    BMC Cancer; 2013 Oct; 13():456. PubMed ID: 24093668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer.
    Sebova K; Zmetakova I; Bella V; Kajo K; Stankovicova I; Kajabova V; Krivulcik T; Lasabova Z; Tomka M; Galbavy S; Fridrichova I
    Cancer Biomark; 2011-2012; 10(1):13-26. PubMed ID: 22297548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CpG island methylator phenotype of multigene in serum of sporadic breast carcinoma.
    Jing F; Yuping W; Yong C; Jie L; Jun L; Xuanbing T; Lihua H
    Tumour Biol; 2010 Aug; 31(4):321-31. PubMed ID: 20490964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
    Lee ES; Issa JP; Roberts DB; Williams MD; Weber RS; Kies MS; El-Naggar AK
    Clin Cancer Res; 2008 May; 14(9):2664-72. PubMed ID: 18451230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.
    Van der Auwera I; Bovie C; Svensson C; Limame R; Trinh XB; van Dam P; Van Laere SJ; Van Marck E; Vermeulen PB; Dirix LY
    Cancer Biol Ther; 2009 Dec; 8(23):2252-9. PubMed ID: 19829046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.